Phacilitate Leaders World


Aron Thall

Aron Thall

Pfizer, Senior Director, Global Clinical Lead, Immuno-Oncology
After receiving a PhD in cell biology/immunology within the Cancer Research Institute of the University of California, San Francisco, Aron Thall conducted post-doctoral studies at the Howard Hughes Medical Institute of the University of Michigan, which led to key publications related to mechanisms of lymphocyte trafficking. He then moved to Boston where he worked mainly within the Harvard/MGH Transplantation Biology Research Center on a number of studies aimed at conditioning the immune system, including early work with immune-checkpoint modulation in primates, leading to multiple publications in peer reviewed journals.  From Boston he moved to IDEC Pharmaceuticals (later BiogenIDEC), where he led the clinical immunology group, focusing on cancer immunotherapies, and was involved with multiple regulatory filings for either new drugs or new indications for existing drugs. Since joining Pfizer in 2008, Aron has had increasing levels of responsibility within the Pfizer Oncology development portfolio and currently is the global clinical lead for combination immunotherapies.
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman